Staphefekt
From Wikipedia, the free encyclopedia
Staphefekt is a proprietary enzyme (an endolysin) intended to treat Staphylococcus aureus skin infections in humans. It is developed and produced by the Dutch biotechnology company Micreos.[1][2] It became the first commercially available endolysin and is marketed in Gladskin products.[3]
The enzyme has been shown to be effective in killing S. aureus strains resistant to antibiotics such as MRSA.[4] The enzyme has successfully been used for treatment of S. aureus-related dermatosis.[5]
